MiMedx Group (MDXG) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Meeting called to order virtually, with board and management expressing appreciation for shareholder attendance.
Meeting format included business proceedings followed by a Q&A session.
Director nominees and senior management introduced; voting procedures and agenda outlined.
Board and executive committee updates
Seven director nominees presented and nominations closed with no other candidates.
Acknowledgment of outgoing board members for their leadership and service.
Shareholder proposals
Election of seven directors to the board.
Advisory vote on executive compensation (say-on-pay) as required by Dodd-Frank Act.
Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MiMedx Group
- Q1 2026 sales fell 33% as wound care plunged 60% and surgical rose 13%, prompting cost cuts.MDXG
Q1 202629 Apr 2026 - Strong sales growth, new product launches, and robust governance highlighted in 2025.MDXG
Proxy filing29 Apr 2026 - Director elections, say-on-pay, and auditor ratification headline the 2026 annual meeting.MDXG
Proxy filing29 Apr 2026 - Record revenue and EBITDA in 2025; surgical growth offsets wound care disruption.MDXG
Q4 20258 Apr 2026 - Strong growth, innovation, and Medicare reform position MiMedx for expanded market leadership.MDXG
TD Cowen 45th Annual Healthcare Conference3 Feb 2026 - Q2 net sales up 7.3% to $87.2M; adjusted EBITDA margin 23%; outlook remains strong.MDXG
Q2 20242 Feb 2026 - Regulatory reform, product innovation, and M&A drive growth amid reimbursement challenges.MDXG
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 net sales up 3% to $84M, 22% EBITDA margin, strong cash and raised guidance.MDXG
Q3 202417 Jan 2026 - New reimbursement rules and clinical innovation drive growth and market leadership.MDXG
Stifel 2024 Healthcare Conference13 Jan 2026